| Literature DB >> 33713813 |
Felipe Ten-Caten1, Patrícia Gonzalez-Dias2, Ícaro Castro2, Rodrigo L T Ogava2, Jeevan Giddaluru2, Juan Carlo S Silva2, Felipe Martins2, André N A Gonçalves3, André G Costa-Martins3, José D Araujo2, Ana Carolina Viegas4, Fernando Q Cunha5, Sandra Farsky2, Fernando A Bozza6, Anna S Levin7, Pia S Pannaraj8, Thushan I de Silva9, Paola Minoprio10, Fabiano Pinheiro da Silva11, Bruno B Andrade12, Helder I Nakaya13.
Abstract
BACKGROUND: The progression and severity of COVID-19 vary significantly in the population. While the hallmarks of SARS-CoV-2 and severe COVID-19 within routine laboratory parameters are emerging, the impact of sex and age on these profiles is still unknown.Entities:
Keywords: COVID-19; Coagulopathy; Infection; Neutrophils; Sex differences
Year: 2021 PMID: 33713813 PMCID: PMC7944763 DOI: 10.1016/j.ijid.2021.03.016
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Figure 1Alterations induced by COVID-19. Volcano plots showing the differences in the levels of laboratory parameters between COVID-19 cases and controls. Female subjects are shown on the top and male subjects on the bottom. The age group is indicated above each volcano plot and the number of individuals is shown in parenthesis. The x-axis shows the log2 fold changes between COVID-19 cases and controls, and the y-axis shows the―log10 adjusted p-values for the analyzed laboratory parameters (dots). Red and blue dots show, respectively, the laboratory parameters that were significantly higher or lower in COVID-19 cases compared with controls (adjusted p-value <0.05 and log2 fold change >0.4).
Figure 2Selected laboratory parameter temporal profiles for male and female COVID-19 patients. The x-axis shows the age of individuals and the y-axis shows the fitted median values (thick line) for the laboratory parameter displayed above each graph. The shaded area represents the 95% confidence interval. Female COVID-19 cases and controls are shown as red and brown lines, respectively. Male COVID-19 cases and control cases are shown as dark blue and light blue lines, respectively. The number of individuals (N) utilized in the analysis, and the Kolmogorov–Smirnov test p-value (K.S.) between the COVID-19 curve and the control curve for each sex are indicated.
Figure 3Analysis of complete blood count tests in COVID-19 cases. The x-axis shows the age of individuals and the y-axis shows the fitted median values (thick line) for the cell type displayed above each graph. The shaded area represents the 95% confidence interval. Female COVID-19 cases and controls are shown as red and brown lines, respectively. Male COVID-19 cases and control cases are shown as dark blue and light blue lines, respectively. The number of individuals (N) utilized in the analysis, and the Kolmogorov–Smirnov test p-value (K.S.) between the COVID-19 curve and the control curve for each sex are indicated.
Figure 4Time course analysis of COVID-19 patients in ICU. (A) Number of days in ICU. Each patient is represented by a green line. The dashed vertical line shows the median number of days in ICU. (B) Number of female and male patients in ICU. Males are represented in blue and females in pink. (C) Age distribution of patients in ICU. (D) Daily records of laboratory parameters in patients admitted to to ICU. The dashed vertical line represents the day of the first record in ICU. Values are shown on the y-axis and the units are displayed in parenthesis on top of each graph. The blue and pink lines represent the median values for male and female COVID-19 patients in ICU, respectively. The shaded area represents the 95% confidence interval. Horizontal dashed lines mark the upper and lower reference normal values for males (blue) and females (pink).
Figure 5Biomarkers of disease activity in COVID-19 patients. (A) Fraction of patients with altered biomarkers of disease activity. Alterations in at least one laboratory parameter for each biomarker of disease activity were detected for male (left) and female (right) COVID-19 patients who were admitted (purple) or not admitted (yellow) to ICU. The graph shows the subjects with alterations as a fraction of the total number of subjects. (B) Number of biomarkers of disease activity detected in COVID-19 patients. The purple and yellow lines indicate, respectively, the fractions of COVID-19 patients who were admitted or not admitted to ICU. (C) Laboratory parameters altered in ICU COVID-19 patients. Each bar represents the fraction of individuals who were admitted (left) or not admitted (right) to ICU, showing values above (red) or below (blue) the normal levels for a specific parameter. Numbers of individuals with alterations are indicated.